Prelude Therapeutics Inc. (PRLD): Price and Financial Metrics
GET POWR RATINGS... FREE!
PRLD Stock Price Chart Interactive Chart >
PRLD Price/Volume Stats
|Current price||$35.50||52-week high||$95.38|
|Prev. close||$33.93||52-week low||$23.69|
|Day high||$36.95||Avg. volume||230,022|
|50-day MA||$33.23||Dividend yield||N/A|
|200-day MA||$47.17||Market Cap||1.67B|
Prelude Therapeutics Inc. (PRLD) Company Bio
Prelude Therapeutics, Inc. operates as a cancer drug discovery company. It focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Gopi Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.
Most Popular Stories View All
PRLD Latest News Stream
|Loading, please wait...|
PRLD Latest Social Stream
View Full PRLD Social Stream
Latest PRLD News From Around the Web
Below are the latest news stories about Prelude Therapeutics Inc that investors may wish to consider to help them evaluate PRLD as an investment opportunity.
David Mauro, Chief Medical Officer at Prelude Therapeutics (NASDAQ:PRLD), made a large buy and sell of company shares on September 7, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission reports that on September 7, David Mauro bought 15,000 Prelude Therapeutics shares at a price of $1.89 per share, for a total of $28,350. They then sold their shares on the same day in the open market at prices ranging from $35.91 to $37.79 to raise a tot
WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences: Morgan Stanley 19th Annual Global Healthcare ConferenceFireside chat at 11:45 a.m. ET on Thursday, September 9, 2021 H.C. Wainwright 23rd Annual Global Investment ConferenceCorporate presentation at 7:00 a.m. ET on Monday, September 13, 2021 A l
- Data from Dose Escalation Portion of Phase 1 Trials of Lead Oral PRMT5 Inhibitors PRT543 and PRT811 to be Presented in 4Q21 – - Enrollment Ongoing in Multiple Expansion Cohorts in Phase 1 Trial of PRT543; Dose Expansion Portion of Phase 1 Trial of PRT811 Expected to Commence in 3Q21 – - Dose Escalation Portion of Phase 1 Trials of Oral and IV Formulations of MCL1 Inhibitor PRT1419 Ongoing – -Strong Cash Position of $343 Million to Support Clinical and Discovery Pipeline Advancement – WILMINGTO
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
WILMINGTON, Del., July 19, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the appointment of Martin Babler to its Board of Directors. Mr. Babler brings to Prelude over 25 years of pharmaceutical and biotech experience, most recently serving as President and Chief Executive Officer of Principia Biopharma until its acquisition by Sanofi S.A. in October 2020. Mr. Babler will serve as a member of the Audit Committee of
PRLD Price Returns